The complement system in the pathogenesis and progression of kidney diseases: What doesn't kill you makes you older.

The Complement System is an evolutionarily conserved component of immunity that plays a key role in host defense against infections and tissue homeostasis. However, the dysfunction of the Complement System can result in tissue damage and inflammation, thereby contributing to the development and progression of various renal diseases, ranging from atypical Hemolytic Uremic Syndrome to glomerulonephritis. Therapeutic interventions targeting the complement system have demonstrated promising results in both preclinical and clinical studies. Currently, several complement inhibitors are being developed for the treatment of complement-mediated renal diseases. This review aims to summarize the most recent insights into complement activation and therapeutic inhibition in renal diseases. Furthermore, it offers potential directions for the future rational use of complement inhibitor drugs in the context of renal diseases.

Informations de copyright

Copyright © 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest EDS invited speakers at meetings supported by Alexion and AstraZeneca. GDE invited speakers at meetings sponsored by Baxter. AM invited speakers at meetings sponsored by AstraZeneca, Travere, and Sanofi. LG received grant support from Abionyx and Sanofi to his university department (DIMEPRE-J); He has been a member of advisory boards for AstraZeneca, Baxter, Chinook, GSK, Mundipharma, Novartis, Pharmadoc, Roche, Sanofi, Travere, Vifor Pharma, and an invited speaker at meetings supported by AstraZeneca, Astellas, Estor, Fresenius, Werfen, Medtronic, Travere, GSK.